Radiomics in precision oncology: hype or ludum mutante
- PMID: 38017483
- PMCID: PMC10683192
- DOI: 10.1186/s12916-023-03165-2
Radiomics in precision oncology: hype or ludum mutante
Keywords: Explainable AI; Imaging; Nasopharyngeal cancer; Precision oncology; Radiomics.
Conflict of interest statement
The authors declare no direct conflict of interest for this work.
Melvin L.K. Chua reports personal fees from Astellas, Janssen, Pfizer, MSD, Varian, IQVIA, Telix Pharmaceuticals; personal fees and research funding to institution from Bayer and BeiGene; personal fees and non-financial support from AstraZeneca; non-financial support from Decipher Biosciences; consults for immunoSCAPE Inc. and PVMed; and is a co-inventor of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837 T), Singapore and serves on the Board of Directors of Digital Life Line Pte Ltd that owns the licensing agreement of the patent, outside the submitted work.
Comment on
-
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study.BMC Med. 2023 Nov 27;21(1):464. doi: 10.1186/s12916-023-03164-3. BMC Med. 2023. PMID: 38012705 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
- NMRC/CSAINV20nov-0021/National Medical Research Council
- Oncology Academic Program Goh Foundation Proton Research Programme/Duke-NUS Medical School
- Cancer Fund/National Cancer Centre of Singapore
- Kua Hong Pak Head/National Cancer Centre of Singapore
- Neck Cancer Research Programme/National Cancer Centre of Singapore
LinkOut - more resources
Full Text Sources